問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of General Internal Medicine

更新時間:2023-09-19

葉裕民Yeh, Yu-Min
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月
  • i5485111@gmail.com

篩選

List

336Cases

2025-10-01 - 2028-12-31

Phase I/II

Not yet recruiting
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)
  • Condition/Disease

    Colorectal Cancer (Diagnosis) 、Colorectal Cancer Metastatic、 Colorectal Cancer (CRC)、 Immunotherapy

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
7Sites

Recruiting7Sites

2020-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-12-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2033-02-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-02-01 - 2025-12-10

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2018-04-02 - 2023-12-06

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-06-01 - 2024-06-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2023-03-01 - 2027-12-31

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2008-11-24 - 2011-08-15

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites